Biblio

Found 19 results
Filters: Keyword is Intracellular Signaling Peptides and Proteins  [Clear All Filters]
2013
Blouin AM, Fried I, Wilson CL, Staba RJ, Behnke EJ, Lam HA, Maidment NT, Karlsson KÆ, Lapierre JL, Siegel JM.  2013.  Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction.. Nature Communications. 4:1547.
Blouin AM, Siegel JM.  2013.  Relation of melanin concentrating hormone levels to sleep, emotion and hypocretin levels.. Sleep. 36(12):1777.
2012
Dell L-A, Patzke N, Bhagwandin A, Bux F, Fuxe K, Barber G, Siegel JM, Manger PR.  2012.  Organization and number of orexinergic neurons in the hypothalamus of two species of Cetartiodactyla: a comparison of giraffe (Giraffa camelopardalis) and harbour porpoise (Phocoena phocoena).. J Chem Neuroanat. 44(2):98-109.
2011
McGregor R, Wu M-F, Barber G, Ramanathan L, Siegel JM.  2011.  Highly specific role of hypocretin (orexin) neurons: differential activation as a function of diurnal phase, operant reinforcement versus operant avoidance and light level.. J Neurosci. 31(43):15455-67.
Siegel JM.  2011.  REM sleep: a biological and psychological paradox.. Sleep Med Rev. 15(3):139-42.
Wu M-F, Nienhuis R, Maidment N, Lam HA, Siegel JM.  2011.  Role of the hypocretin (orexin) receptor 2 (Hcrt-r2) in the regulation of hypocretin level and cataplexy.. J Neurosci. 31(17):6305-10.
2009
Scammell TE, Willie JT, Guilleminault C, Siegel JM.  2009.  A consensus definition of cataplexy in mouse models of narcolepsy.. Sleep. 32(1):111-6.
Thannickal TC, Nienhuis R, Siegel JM.  2009.  Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy.. Sleep. 32(8):993-8.
2008
Thannickal TC, Lai Y-Y, Siegel JM.  2008.  Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinson's disease.. Brain. 131(Pt 1):e87.
2007
Thannickal TC, Lai Y-Y, Siegel JM.  2007.  Hypocretin (orexin) cell loss in Parkinson's disease.. Brain. 130(Pt 6):1586-95.
Deadwyler SA, Porrino L, Siegel JM, Hampson RE.  2007.  Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates.. J Neurosci. 27(52):14239-47.
2005
Mileykovskiy BY, Kiyashchenko LI, Siegel JM.  2005.  Behavioral correlates of activity in identified hypocretin/orexin neurons.. Neuron. 46(5):787-98.
Blouin AM, Thannickal TC, Worley PF, Baraban JM, Reti IM, Siegel JM.  2005.  Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy.. Neurology. 65(8):1189-92.
2004
Siegel JM.  2004.  Hypocretin (orexin): role in normal behavior and neuropathology.. Annual Reviews of Psychology. 55:125-48.
2003
Thannickal TC, Siegel JM, Nienhuis R, Moore RY.  2003.  Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy.. Brain Pathology. 13(3):340-51.
2000
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM.  2000.  Reduced number of hypocretin neurons in human narcolepsy.. Neuron. 27(3):469-74.
John J, Wu MF, Siegel JM.  2000.  Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs.. Sleep Res Online. 3(1):23-8.